Evidence map›Paper›PMID 40859844›Full record

ArticleStroke2025

Preclinical Evidence of Nogo-A Inhibition in Stroke Recovery: A Scoping Review.

José Eduardo E Lima, Sophie Rengarajan, Anna-Sophia Wahl, Aditya Srivatsan, Stephen M Strittmatter, S Tom Carmichael, Paul M George, Kevin N Sheth, Martin E Schwab, Maarten G Lansberg

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

José Eduardo E Lima *Department of Neurology, Stanford University, Palo Alto, CA (J.E.E.L., S.R., A.S., P.M.G., M.G.L.).
Sophie Rengarajan *Department of Neurology, Stanford University, Palo Alto, CA (J.E.E.L., S.R., A.S., P.M.G., M.G.L.).
Anna-Sophia WahlLudwig-Maximilian University of Munich, Institute for Stroke and Dementia Research, Germany (A.-S.W.).ORCID 0000-0001-9498-4263
Aditya SrivatsanDepartment of Neurology, Stanford University, Palo Alto, CA (J.E.E.L., S.R., A.S., P.M.G., M.G.L.).
Stephen M StrittmatterDepartment of Neuroscience (S.M.S.), Yale University, New Haven, CT.ORCID 0000-0001-8188-3092
S Tom CarmichaelDepartment of Neurology, University of California Los Angeles (S.R., S.T.C.).ORCID 0000-0002-1169-9203
Paul M GeorgeDepartment of Neurology, Stanford University, Palo Alto, CA (J.E.E.L., S.R., A.S., P.M.G., M.G.L.).ORCID 0000-0002-1080-098X
Kevin N ShethDepartment of Neurology, Yale Center for Brain & Mind Health (S.M.S., K.N.S.), Yale University, New Haven, CT.ORCID 0000-0003-2003-5473
Martin E SchwabUniversity of Zurich, Institute for Regenerative Medicine, Switzerland (M.E.S.).ORCID 0000-0001-6206-6150
Maarten G LansbergDepartment of Neurology, Stanford University, Palo Alto, CA (J.E.E.L., S.R., A.S., P.M.G., M.G.L.).ORCID 0000-0002-3545-6927

Funding

Genome-Wide Discovery and Translational Research for Neural RepairR35NS097283 · NINDS · YALE UNIVERSITY · PI STRITTMATTER, STEPHEN M · 2017 to 2024
$8.1M
Stanford University Regional Coordinating Stroke Center for the NIH Stroke Trials NetworkU24NS107220 · NINDS · STANFORD UNIVERSITY · PI MAARTEN G LANSBERG · 2018 to 2026
$2.8M
NINDS NIH HHS R35 NS097283NINDS NIH HHS U24 NS107220
6 · The paper itself

Abstract

Stroke is one of the leading causes of disability worldwide. Although preclinical studies have shown promising results of pharmacotherapies to enhance stroke recovery, no drug has been approved for stroke recovery in patients. In this article, we review the preclinical data of one promising treatment, inhibition of NgR1 (Nogo receptor 1) signaling, for stroke recovery. Our scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews and surveyed the peer-reviewed literature on PubMed and citation searching. Studies were eligible if they evaluated the pharmacological inhibition of Nogo/NgR1 signaling in nonhuman models of stroke assessing sensorimotor or functional outcomes. There were no restrictions in years considered. An assessment of the risk of bias was performed using the Systematic Review center for Laboratory Animal Experimentation tool. Three hundred seventeen articles were screened based on the inclusion criteria. Thirty preclinical studies were included. Most studies (90%) were conducted in rodents, with only 3 studies (10%) completed in nonhuman primates. Anti-Nogo-A antibody was the most common pharmacological intervention, used in 21 (70%) studies. Most preclinical studies delivered the study drug directly into the central nervous system (intrathecal, intraventricular, or intraparenchymal), with far fewer studies (n=5) testing subcutaneous, intravenous, or intranasal administration. Among the 30 studies included, 27 (90%) report a beneficial effect. In conclusion, there is a large body of preclinical evidence to support Nogo/NgR1 inhibition in promoting stroke recovery. A clinical trial to assess the safety, feasibility, and efficacy among patients with stroke is warranted.

Indexed as

Nogo ProteinsNogo Receptor 1Recovery of FunctionStrokeAnimalsDisease Models, AnimalHumansNogo ProteinsNogo Receptor 1brain regenerationischemic strokeNogo receptor 1stroke rehabilitation

Identifiers

PMID40859844
PMCPMC12536797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.